Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Next Previous
Trial Profile

An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod alfa (Primary)
  • Indications Myasthenia gravis
  • Focus Expanded access; Therapeutic Use
  • Sponsors argenx

Most Recent Events

  • 26 Apr 2022 Results (As of September 24, 2021,n= 10 )presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 25 Apr 2022 Status changed from recruiting to completed.
  • 01 Apr 2022 According to an argenx media release, data from this trial will be presented at the American Academy of Neurology (AAN) Annual Meeting in Seattle; the meeting abstracts are available online and can be accessed through the AAN meeting website at AAN.com.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top